- Title: Subtitle
- POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
- Creators
- Mohamad MohtyMichael H. TomassonBertrand ArnulfNizar J. BahlisH. Miles PrinceRuben NiesvizkyPaula Rodrίguez-OteroJoaquin Martinez-LopezGuenther KoehneYogesh JethavaAfshin E. GabayanDon A. StevensAjay K. NookaNoopur RajeShinsuke IidaEric LeipUmberto ConteAkos CzibereAndrea ViqueiraAlexander M. Lesokhin
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.23(Suppl. 1), pp.S225-S225
- Publisher
- Elsevier Inc
- DOI
- 10.1016/S2152-2650(23)00860-1
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Date published
- 09/2023
- Academic Unit
- Internal Medicine; Health and Human Physiology; Hematology, Oncology, and Blood & Marrow Transplantation
- Record Identifier
- 9984461212902771
Abstract
POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
Clinical lymphoma, myeloma and leukemia, Vol.23(Suppl. 1), pp.S225-S225
09/2023
DOI: 10.1016/S2152-2650(23)00860-1
Details
Metrics
5 Record Views